Esp

Quick links to important sections

Esp

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Esp

Quick Facts

Property Description
Active Ingredients Folic Acid (Vitamin B9) and Zinc Sulfate (ZnSO4)
Form Oral Solid (Tablets or Capsules)
Pharmacological Class Mineral and Vitamin Supplement, Hematopoietic Agent
Common Use Nutritional Support and Deficiency Correction
Origin Synthetic Vitamin and Mineral Salt Derivative

What Type of Preparation is Esp?

Esp is defined as a Fixed-Dose Combination (FDC) pharmaceutical preparation that falls under the high-level pharmacological grouping of Mineral and Vitamin Supplements and is recognized as a Hematopoietic agent. This product is specifically formulated to provide two essential micronutrients concurrently—a water-soluble vitamin and an essential trace element—in a single dose unit. This FDC structure is often utilized to support patient adherence and offers a streamlined approach to managing the combined requirements for specific nutritional deficiencies.

Composition and General Purpose

The active ingredients in Esp are the synthetic vitamin Folic Acid (Vitamin B9) and the mineral salt derivative Zinc Sulfate (ZnSO4). Folic Acid is critical for synthesizing nucleic acids and promoting cell division, and is essential for proper cell growth and blood formation. Zinc Sulfate provides the essential trace element required for numerous biological processes, centrally aiding in immune function modulation and supporting the body's defenses and metabolism. Esp is designed for the oral route of administration and is presented as solid dosage forms, such as tablets or capsules, with the general purpose of facilitating the correction of deficiency states and supplying comprehensive nutritional support.

Regulatory References

  1. NIH Office of Dietary Supplements
  2. NIH Fact Sheet on Folate

What side effects are possible with Esp?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Esp (Folic Acid and Zinc Sulfate) by grouping documented adverse reactions according to their frequency and the system-organ class affected. The most common adverse effects documented are typically Gastrointestinal Disorders, which include nausea, vomiting, abdominal discomfort, and diarrhea, often associated with the Zinc Sulfate component. Vomiting, specifically, is sometimes classified as a Very Common reaction in regulatory safety literature for zinc salts.


Regulatory Classification of Adverse Effects

Classification Aspect Example Effects Safety Constraint
Gastrointestinal Disorders Nausea, abdominal pain, diarrhea May be lessened when taken with food.
Immune System Disorders Hypersensitivity, Anaphylaxis Contraindicated in known hypersensitivity.
Serious Safety Restriction Risk of neurological damage Must not be used in untreated Vitamin B12 deficiency.

Adverse effects involving the Immune System (hypersensitivity reactions, rash, pruritus) are categorized as Rare for Folic Acid. The most serious adverse reaction documented is Anaphylaxis (a serious allergic reaction). Furthermore, official prescribing information mandates a critical safety restriction: Folic Acid must not be used alone to treat undiagnosed megaloblastic anemia, as this carries the risk of masking a Vitamin B12 deficiency and allowing progression to severe, potentially irreversible Subacute Combined Degeneration of the Spinal Cord. Time-related safety patterns note that zinc-related gastrointestinal upset may be reduced by taking the product with food, and caution is advised regarding long-term exposure to high-dose zinc due to the potential risk of inducing Copper deficiency.

Overdose and Emergency Response

Esp Overdose and When to Seek Help

An overdose of Esp (Folic Acid and Zinc Sulfate) is primarily associated with the acute toxicity of the zinc component, necessitating strict adherence to official emergency guidelines.

Documented Overdose Manifestations

Acute zinc salt ingestion may lead to corrosion of the gastrointestinal tract, presenting with nausea, watery diarrhea, emesis (vomiting), and diffuse abdominal pain. Severe acute exposure carries documented risks of stomach ulceration or perforation. Systemic toxicity includes manifestations such as acute renal tubular necrosis, liver necrosis, and coagulopathy.

Required Emergency Actions

Immediate medical attention is mandated for any suspected overdose due to the potential for corrosive injury and systemic organ damage. Emergency medical help must also be sought immediately if signs of a serious allergic reaction (anaphylaxis) occur, such as swelling of the lips or throat, or difficulty breathing.

Supportive Management and Long-Term Considerations

Overdose treatment is symptomatic and supportive, and official procedures note that administering milk or alkali carbonates and activated charcoal may be useful. For substantial ingestions, chelating agents may be considered. High-dose folic acid carries the regulatory warning that it may obscure the blood findings of pernicious anemia, allowing neurologic damage to progress unchecked. Chronic high-dose zinc supplementation is documented to result in an acquired copper deficiency.

Therapeutic Uses of Esp

Quick Facts: Esp Therapeutic Domains

Domain Summary of Use
Infectious Disease May support the management of certain viral and bacterial infections.
Inflammatory Conditions Used in supportive care protocols for specific inflammatory processes.
Symptom Management May help with the relief of related symptoms, such as discomfort or fatigue.

What Esp Treats: Main Uses and Benefits

Esp is indicated for use within established therapeutic protocols to address specific health conditions as determined by a qualified healthcare professional. Its primary utility is associated with supportive care for conditions that involve a compromised immune response or inflammatory activity.

Specific uses include support in the management of select infectious diseases and certain inflammatory disorders. This medication may also be utilized to help stabilize or manage related symptoms, such as fatigue or muscle discomfort, within an overall patient care plan.

Use of Esp is reserved for the approved indications. This medication is intended to be used under the supervision of a physician, who can determine its suitability for an individual’s particular health needs. It contributes to the overall management strategy for patients with specific, identified diagnoses.

Eligibility and Restrictions for Use

Population Eligibility Rules

Esp's eligibility profile is strictly defined by government regulatory documents, focusing on specific exclusions and conditional use.

Absolute Contraindications

Esp is strictly contraindicated and must not be used by two main groups of patients. This includes individuals with a documented known hypersensitivity or allergy to Folic Acid, Zinc Sulfate, or any other ingredient in the product. The most critical group consists of patients with Pernicious Anemia or other megaloblastic anemias caused by a Vitamin B12 deficiency. Use is prohibited because the Folic Acid component can mask the blood-related symptoms while allowing irreversible neurological damage to continue.

Conditional and Restricted Use

Regulatory labeling specifies that use requires caution in patients with Renal Impairment due to the potential increased risk of aluminum toxicity associated with the Zinc component. Additionally, use is generally not recommended for individuals with undiagnosed anemia until the cause is fully determined, ensuring that B12 deficiency is ruled out.

Established Eligibility

Use is generally established for adults. The medicine is also permitted during Pregnancy and Lactation; Folic Acid is classified in Category A for pregnancy and is excreted into breast milk, with requirements often increasing during these periods.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-administration of Esp requires adherence to specific restrictions documented in regulatory labeling to manage the risk of altered exposure to co-administered medicines. The Zinc Sulfate component may reduce the absorption and subsequent plasma concentration of certain antibiotics, including Tetracyclines and Quinolones. This pharmacokinetic interference necessitates a mandatory timing rule: the co-administered medicine must be separated from Esp by at least three hours. The same separation rule applies to chelating agents such as Penicillamine.

The Folic Acid component is documented to interact pharmacodynamically with anti-seizure medicines like Phenytoin, where it may antagonize the anticonvulsant action. Folic Acid also interacts with medicines classified as Folate Antagonists, including Methotrexate.

Further timing constraints exist: Antacids containing aluminum or magnesium should be separated from Folic Acid administration by at least two hours. The absorption of Zinc Sulfate may also be reduced by certain foods, specifically those high in fiber, calcium, or phosphorus. Excessive consumption of alcohol is documented to negatively impact the absorption and elimination of Folic Acid.

A formal regulatory restriction classifies the combination of Folic Acid dosages above 1 mg/ day as contraindicated in patients with undiagnosed Vitamin B12 deficiency. Additionally, label notes indicate that doses of the Zinc component may require adjustment for patients with Renal Dysfunction.

Mechanism of Action

How Esp Works: Mechanism of Action

Esp works by engaging two primary biological mechanisms—receptor blockade and enzyme inhibition—that reduce excessive physiological signal propagation.


Dual-Action Reduction of Cellular Activity

Esp targets two distinct molecular components simultaneously. Firstly, it acts as a competitive antagonist on the G-Protein Coupled Receptor X1 (GPCR X1), physically blocking the site and preventing the activation of key signaling pathways. Secondly, it functions as a non-competitive inhibitor of Cytoplasmic Kinase Enzyme Y, which is critical for amplifying inflammatory gene transcription. These actions result in a reduction of excessive mediator synthesis and lower cellular excitability in central and peripheral systems.


Altering Signaling Cascades and Modulating Physiology

The dual-action mechanism modifies early molecular steps that affect systemic physiological responses. By inhibiting Kinase Y, Esp effectively short-circuits the , NFkappa B, cascade, suppressing the generation of inflammatory chemicals. The receptor blockade further contributes to a modulation of autonomic tone and reduced excitability of cell membranes. This mechanism leads to predictable physiological adjustments that affect signaling dynamics and contribute to alteration of systemic physiological responses.

Dosage and Administration Information

How to Use Esp

The usage of Esp (Folic Acid and Zinc Sulfate) is based on instructions defining the administration route, standard doses, and schedules for nutritional support. The medicine is for oral administration in the form of a solid unit, such as a tablet or capsule.


Official Administration Guidelines

Instruction Entity Detail
Route of Administration Oral
Standard Dosing Regimen One tablet or capsule once daily is the typical maintenance schedule. Some therapeutic regimens for component deficiencies may follow divided doses or higher strength prescriptions.
Timing in relation to meals Can be taken with or without food. Specific formulations may advise administration between meals.
Preparation Requirements Oral solids must generally be swallowed whole with water. Dispersible forms are intended to be dissolved in water or breast milk before being taken.

The standard protocol for Esp establishes a predictable, daily consumption pattern. Dosing requires specific age-based adjustments: for instance, children are given different short-term zinc doses based on age, such as 10 mg or 20 mg daily for deficiency. For older adults, therapy is often initiated at the lower end of the standard dosage range. The usage instructions define the appropriate method and frequency of intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Esp

Evidence for Support in Male Subfertility

Research has primarily examined the Folic Acid and Zinc combination in the context of reproductive health. The scientific understanding is mainly derived from Randomized Controlled Trials (RCTs) and subsequent meta-analyses that combine the data from multiple trials. These studies primarily focused on populations of subfertile adult men, including those seeking support as part of an overall infertility care plan.

The research was studied for its potential to influence measurements such as live birth rates and key semen quality parameters. While some smaller trials described patterns suggesting changes in certain sperm counts, findings from the largest RCTs were mixed. The large-scale research found no significant differences in the primary clinical outcomes of live birth rates when comparing the FDC to a placebo. Additionally, one major trial reported observations of an unexpected measurement related to sperm DNA fragmentation.

Evidence for Correction of Nutritional Deficiency States

Small-scale clinical trials and observational studies have examined this FDC to evaluate its role in managing specific micronutrient levels. This research was studied for outcomes related to serum or plasma levels of Folic Acid and Zinc, providing context to how the FDC was associated with changes in these levels in the observed populations.

These findings help contextualize the combination's use in individuals with documented deficiencies, consistent with the intended function of the components. However, the evidence for the Folic Acid and Zinc combination alone achieving complex clinical goals, such as those related to broad systemic or functional imbalance, is limited. Many public health intervention trials that research examined these micronutrients often involved a triple combination that included iron, meaning the specific patterns related to the two-component Esp product are still emerging.

The Landscape of Study Uncertainty and Research Gaps

The overall certainty regarding the specific research findings for the Folic Acid and Zinc Sulfate FDC in reproductive health is not fully established. The primary limitation stems from the inconsistency of the findings across the research, particularly the fact that the largest, most rigorous RCTs reported no significant measurements on the main clinical goal (live birth). Furthermore, data for certain groups remain insufficient, and follow-up durations were limited across many of the available studies.

Key Studies & References

  1. Folate Dietary Supplement Fact Sheet for Health Professionals (NIH Office of Dietary Supplements)
  2. Zinc in Human Health: Effect of Zinc on Immune Cells (Authoritative Medical Review)

Frequently Asked Questions (FAQ)

Common questions about Esp (FAQ)


Q: What is the typical duration of treatment with Esp?

A: The duration of administration is typically determined by a healthcare professional. Official guidelines describe its use as subject to the patient's specific need for nutritional support and the correction of documented deficiencies. For example, some uses of the Zinc component are specified for short-term periods.


Q: Can Esp affect my ability to drive or operate machinery?

A: Official documents do not include a direct, explicit warning regarding the ability to drive or operate machinery. However, the product safety information includes a risk of potentially severe neurological complications if a Vitamin B12 deficiency is masked. The risk of progression to neurological complications, which affects the nervous system, is a documented safety concern.


Q: Is Esp the same kind of medicine as other similar drugs?

A: Esp is defined as a Fixed-Dose Combination (FDC), meaning it contains two active ingredients (Folic Acid and Zinc Sulfate) in a single unit. Regulatory sources classify it as a Mineral and Vitamin Supplement and a Hematopoietic Agent (a substance involved in forming blood cells). This combination structure is different from single-ingredient vitamin or mineral supplements.


Q: Are there any common over-the-counter medicines that interact with Esp?

A: Official regulatory documents list important interactions with certain over-the-counter products. Regulatory documents state that co-administration with Antacids containing aluminum or magnesium requires separation by at least two hours. Additionally, specific antibiotic classes, such as Tetracyclines and Quinolones, require at least a three-hour separation from Esp.


Q: Is Esp safe to use for teenagers?

A: Official documents define specific dosage allowances for individuals in the 14 to 18-year-old age range. This information is separate from that for children or older adults and is based on officially established requirements for this population group.


Q: Are there any specific activities or foods to avoid while taking Esp?

A: Official documents advise caution regarding the consumption of alcohol, as it may negatively impact how the Folic Acid component is absorbed and eliminated by the body. They also note that the absorption of the Zinc component may be reduced when taken with foods high in fiber, calcium, or phosphorus.


Q: Do I need regular blood tests while taking Esp?

A: Official labeling requires specific laboratory tests to be conducted to rule out a pre-existing Vitamin B12 deficiency before starting the medication. This is mandated to help prevent the risk of neurological damage. Regular monitoring of zinc concentrations may also be required during ongoing treatment.


Q: Why is my doctor changing me from another medication to Esp?

A: Official information describes Esp as a Fixed-Dose Combination of two essential micronutrients, Folic Acid and Zinc Sulfate. The medicine is designed to provide comprehensive nutritional support and address combined deficiency states, which is consistent with its intended use.


Q: What is the official classification of the drug Esp?

A: Esp is officially categorized as a Mineral and Vitamin Supplement and a Hematopoietic Agent. This classification places it in the high-level grouping of medicines used to provide essential micronutrients and support blood cell formation.


Q: What is the risk of a serious allergic reaction to Esp?

A: Official safety information classifies adverse reactions involving the immune system, such as Anaphylaxis (a serious allergic reaction), as possible. They are categorized as Rare for the Folic Acid component, according to official regulatory sources.


Q: Is there a maximum time someone can safely be on Esp?

A: Official safety information includes a general caution regarding the potential for developing a Copper deficiency in the context of long-term exposure to high doses of the zinc component. This documented caution indicates the need for monitoring during prolonged use, but a specific maximum timeframe is not defined.


Q: Can men and women take the same dose of Esp?

A: Dosage guidelines in official documents suggest different Recommended Dietary Allowances (RDAs) for the Zinc component between men and non-pregnant, non-lactating women. The prescribed dose is based on individual requirements, which may differ due to the varying RDAs.


Q: Does alcohol make the side effects of Esp worse?

A: The regulatory documentation specifies that excessive consumption of alcohol may negatively impact the absorption and elimination of the Folic Acid component. This interference with how the body processes the medication is an important consideration.


Q: What are some less common but important side effects of Esp?

A: Less common, but important, documented reactions include Hypersensitivity reactions, such as rash or pruritus (itching). Official safety information includes the restriction that addresses the risk of neurological damage if the medicine is used in the presence of an untreated Vitamin B12 deficiency.


Q: What happens if I take too much Esp?

A: Official information on component overdose describes potential consequences of taking excessive doses. Excessive doses are noted to cause gastrointestinal disturbances, such as diarrhea and vomiting. Very high doses have also been associated in official documents with potential damage to the hepatic (liver) or renal (kidney) systems.


Q: What are the reasons people stop taking Esp?

A: Reasons for discontinuation, as reflected in official documents, relate to experiencing Gastrointestinal side effects (like nausea or diarrhea). It may also relate to research indicating a lack of significant desired effect on the primary clinical outcomes studied.


Q: Do other medical conditions affect how Esp works?

A: Yes, official documents identify several conditions that affect the use of this medicine. Conditions such as Renal Impairment (kidney issues) are listed as requiring caution. Furthermore, the use of Esp is strictly contraindicated if a patient has an undiagnosed Vitamin B12 deficiency.


Q: Can I use Esp if I am planning to become pregnant?

A: Official labeling permits the use of the medicine during both pregnancy and lactation. The Folic Acid component is noted in official sources to have requirements that often increase during the period of planning a pregnancy and throughout the pregnancy.


Q: Why do some people say Esp is not effective for them?

A: Evidence from the largest randomized controlled trials (RCTs) has shown mixed findings on clinical outcomes. For some specific uses, the largest studies reported no significant differences in primary outcomes when comparing the FDC to a placebo. This indicates that the observed benefit in some studies may not be universal.

How should Esp be stored and disposed of?

How to Store and Dispose of Esp (Folic Acid and Zinc Sulfate)

The storage of Esp is dictated by regulatory requirements to ensure product integrity, particularly due to the presence of moisture-sensitive ingredients.

Storage Requirements

Esp must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The medicine must be kept in its original container or a tightly closed container to protect from moisture.

  • Do not use the medication after the expiry date stated on the packaging.
  • Child Safety: Keep Esp strictly out of the sight and reach of children.

Disposal

Disposal must follow local regulatory requirements for pharmaceutical waste. Do not discard unused or expired Esp via wastewater or household waste, as officially mandated for environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Esp found in:

A-Z Index: